A5069716824- Blood properties and coagulation
- Diagnosis and Treatment of Venous Diseases
- Venous Thromboembolism Diagnosis and Management
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- Bladder and Urothelial Cancer Treatments
- Cancer Treatment and Pharmacology
- Synthesis and Biological Activity
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Heterotopic Ossification and Related Conditions
- Radiopharmaceutical Chemistry and Applications
- Epigenetics and DNA Methylation
- Intestinal and Peritoneal Adhesions
- Trypanosoma species research and implications
- Colorectal and Anal Carcinomas
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Intraperitoneal and Appendiceal Malignancies
- Parathyroid Disorders and Treatments
- Prostate Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Medical Imaging and Pathology Studies
- Colorectal Cancer Surgical Treatments
- Hormonal and reproductive studies
Azienda Ospedaliero-Universitaria Careggi
2024
Hospital de Sant Pau
2012-2023
Spanish Ovarian Cancer Research Group
2023
Princess Margaret Cancer Centre
2015
Hospital Clínico Universitario Lozano Blesa
1999
PURPOSE The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer demonstrated a significant progression-free survival (PFS) benefit over placebo bevacizumab, particularly in patients with homologous recombination deficiency (HRD)–positive tumors. We explored whether mutations non- BRCA1 or BRCA2 repair (non–BRCA HRRm) genes predicted from PAOLA-1. METHODS Eight hundred and six were randomly assigned (2:1). Tumors analyzed...
3064 Background: ICIs are associated with irAEs. We describe the incidence of irAEs in patients solid tumors receiving and its correlation efficacy. Methods: retrospectively analyzed all our center. IrAEs were graded according CTCAE v4.0. Kaplan Meier log-rank tests used to evaluate progression-free (PFS) overall survivals (OS). Analyses performed using SPSS v24 package. Results: From March 2014 January 2018, 178 received ICIs. Median age was 64.1 [33-88] years, 72% male. Most frequent lung...
e16586 Background: Ovarian cancer (OC) is the leading cause of death from gynecological and fifth mortality in women Canada. MBO a common (20-50% incidence) disturbing complication with advanced OC. The management recurrent OC represents major clinical challenge limited or no level 1 evidence to guide management. Methods: A detailed medical records review admitted EOC Princess Margaret Cancer Centre Toronto General Hospital January 2009 December 2013 was performed assess predictors outcomes...
e16049 Background: Recent development of new second line therapies in patients with CRPC upon progression to docetaxel has raised the question who benefit most either a salvage hormonal treatment (HT) or chemotherapy. Objectives: To analyze prognostic value for survival absolute levels serum testosterone (TL) under definition (PSA and/or clinical TL <50 ng/dL). probability response HT failure docetaxel. Methods: 101 metastatic were included 9 different non-hormonal first phase II-III...
In recent years, there have been rheological abnormalities reported in chronic venous insufficiency (CVI), mainly an increase of erythrocyte aggregability (EA), which probably take part the pathophysiology disease. The aim this study was to analyze hemorheological profile after stripping 45 patients suffering from CVI. Follow-up included laboratory tests on 7th, 60th and 180th day surgery. EA assessed with a photometric aggregometer (MA1, Myrenne) stasis low shear (3 s(-1)). results show 7th...
e15001 Background: Platinum-based chemotherapy (CT) is beneficial as first-line treatment of advanced UC. However, the majority patients develop recurrent disease with poor long-term survival rates. Attempts to improve second-line treatments have evaluated single agents and multi-drug combinations, neither which has managed or achieve durable responses. Z a cytotoxic agent that induces apoptosis by acting at cell cycle level, DNA-binding properties inhibits transcriptional shown anti-tumor...
TPS4672 Background: Advanced transitional cell carcinoma of the urothelium (TCCU) on progression after previous cisplatin-based combination is generally an incurable disease. The appropriate management these patients still unmet need. Many drugs have shown modest or no activity in phase 2 trials. Population heterogeneity studies emerges as one key determinants that could explain variable outcomes. Recently, a III study this setting, prognostic factors (PF) for overall survival were...
e15159 Background: To analyze the prognostic value for survival of absolute levels serum testosterone in patients under definition CRPC (PSA and/or clinical progression with a level below 50 ng/dL). Methods: 49 were included 4 non-hormonal first line phase II-III trials our institution since August 2006 until Jan 2012 metastatic CRPC. Inclusion criteria those uniformly required castrate testosterone. Survival was calculated date entrance trial. Results: Median age 71 years (53-89). 9/49...
Background: In recent years, pathophysiological studies and treatment approaches of chronic venous insufficiency (CVI) have focused on haemorheology. Objective: To analyse erythrocyte aggregation (EA) blood viscosity (BV) in mild severe stages CVI. Methods: 147 patients (three severity stages), EA was measured with a photometric aggregometer, BV cone-plate viscosimeter. Patients concomitant pathologies affecting haemorheology were excluded. Results: higher (mean 10M: 16.4 vs 14.5 control),...